3.0.0 5894 2022-02-08T23:54:43Z 2022-02-08T23:54:43Z House HR 2020-02-13 116 [Congressional Record Volume 166, Number 30 (Thursday, February 13, 2020)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Ms. DAVIDS:H.R. 5894.Congress has the power to enact this legislation pursuantto the following:This bill is enacted pursuant to the power granted toCongress under Article I, Section 8, Clause 18 of the UnitedStates Constitution.[Page H1157]]]> hsif00 Energy and Commerce Committee House Standing Referred to 2020-02-13T14:02:05Z 2020-02-13 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2020-02-13 Introduced in House IntroReferral Intro-H 9 Library of Congress 2020-02-13 Introduced in House IntroReferral 1000 9 Library of Congress D000629 Rep. Davids, Sharice [D-KS-3] Sharice Davids D KS 3 N S001208 Rep. Slotkin, Elissa [D-MI-8] Elissa Slotkin D MI 8 2020-02-13 True F000467 Rep. Finkenauer, Abby [D-IA-1] Abby Finkenauer D IA 1 2020-02-13 True P000593 Rep. Perlmutter, Ed [D-CO-7] Ed Perlmutter D CO 7 2020-05-01 False Health Drug safety, medical device, and laboratory regulation Inflation and prices Marketing and advertising Prescription drugs Health 00 2020-02-13 Introduced in House 2020-08-12T21:23:46Z Transparency in Prescription Drug Advertising Act

This bill requires that the list prices of drugs be included, as appropriate, in advertising for such drugs and directs the Department of Health and Human Services to issue department-wide guidance to that effect that is consistent with regulations issued by the Centers for Medicare & Medicaid Services (CMS) regarding drug price transparency.

On May 10, 2019, the CMS issued a final rule titled Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency. The rule requires direct-to-consumer television advertisements for drugs and biologics covered under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least $35 per month. The rule was scheduled to take effect on July 9, 2019; however, a federal court blocked the rule's implementation, citing a lack of statutory authority.

]]> Transparency in Prescription Drug Advertising Act Display Title Transparency in Prescription Drug Advertising Act Official Title as Introduced To direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs. Introduced in House IH Short Title(s) as Introduced Transparency in Prescription Drug Advertising Act Introduced in House IH Introduced in House 2020-02-13T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr5894ih/xml/BILLS-116hr5894ih.xml 2020-02-13 Referred to the House Committee on Energy and Commerce. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.